相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Oral corticosteroid elimination via a personalised reduction algorithm in adults with severe, eosinophilic asthma treated with benralizumab (PONENTE): a multicentre, open-label, single-arm study
Andrew Menzies-Gow et al.
LANCET RESPIRATORY MEDICINE (2022)
Derivation of a prototype asthma attack risk scale centred on blood eosinophils and exhaled nitric oxide
Simon Couillard et al.
THORAX (2022)
Evaluation of the oral corticosteroid-sparing effect of tezepelumab in adults with oral corticosteroid-dependent asthma (SOURCE): a randomised, placebo-controlled, phase 3 study
Michael E. Wechsler et al.
LANCET RESPIRATORY MEDICINE (2022)
Predicting the benefits of type-2 targeted anti-inflammatory treatment with the prototype Oxford Asthma Attack Risk Scale (ORACLE)
Simon Couillard et al.
ERJ OPEN RESEARCH (2022)
Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma
Andrew Menzies-Gow et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Fractional Exhaled Nitric Oxide Nonsuppression Identifies Corticosteroid-Resistant Type 2 Signaling in Severe Asthma
Simon Couillard et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2021)
Workup of Severe Asthma
Simon Couillard et al.
CHEST (2021)
Patient characteristics, biomarkers and exacerbation risk in severe, uncontrolled asthma
Monica Kraft et al.
EUROPEAN RESPIRATORY JOURNAL (2021)
Prognostic and Predictive Value of Blood Eosinophil Count, Fractional Exhaled Nitric Oxide, and Their Combination in Severe Asthma: A Post Hoc Analysis
Rahul Shrimanker et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2019)
Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies
Hector G. Ortega et al.
LANCET RESPIRATORY MEDICINE (2016)
Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma
Hector G. Ortega et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)